ClinicalTrials.gg
CompletedNCT05813977Updated Jul 9, 2025

Amount of Droplet Formed During Percutaneous Dilatational Tracheostomy

An interventional study of tritube in Ventilatory Failure, sponsored by Ankara Diskapi Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Ankara Diskapi Training and Research Hospital · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

During the percutaneous dilatational tracheostomy (PDT), large amount of droplets and aerosols are spread to the environment especially with the effect of ventilation during the dilatation phase. In such cases, it is recommended to take precautions such as masks and goggles or shields to protect practitioners from infection, however it has also been reported that droplets and aerosols can spread to the environment and can go far.

Flow controlled ventilation (FCV) with the use of Tritube® and Evone® could reduce droplet spread during PDT and provide a safer environment while operating on patients with infected airways.

Read the detailed description

During the percutaneous dilatational tracheostomy, large amount of droplets and aerosols are spread to the environment especially with the effect of ventilation during the dilatation phase. In such cases, it is recommended to take precautions such as masks and goggles or shields to protect practitioners from infection, however it has also been reported that droplets and aerosols can spread to the environment and can go far.

Flow controlled ventilation (FCV) with the use of Tritube® and Evone® could reduce droplet spread during PDT and provide a safer environment while operating on patients with infected airways.

SPSS 21.0 (Statistical Package for the Social Sciences) (Version 22.0, SPSS, Inc, Chicago, USA) program will be used for statistical analysis. After applying the Shapiro-wilk test for normality, the student's t test will be used if the distribution is not normal. Fisher's exact test or chi-square test will be used for categorical variables. Results p\<0.05 will be considered significant.

The investigators compared the amount of droplets scattered in the environment with PDT performed with FCV and conventional mechanical ventilation methods, with the ATP (adenosine triphosphate) bioluminescence method.

02

Conditions studied

  • Ventilatory Failure

Browse trials for

Keywords

  • Percutaneous Dilatational Tracheotomy
  • Flow controlled ventilation
  • droplet
03

In context

Hypoventilation

96 studies on the registry are indexed under Hypoventilation; 21 are open to participants now.

This study's enrollment of 39 is below the median of 52 across 63 interventional studies indexed under Hypoventilation.

Browse Hypoventilation studies →

Lead sponsor

Ankara Diskapi Training and Research Hospital is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • percutaneous tracheostomy procedure

Exclusion criteria

Exclusion Criteria:

  • whose written consent cannot be obtained
  • who undergo surgical tracheostomy for any reason
  • patients with active infection in the area of the procedure
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Group 1: Tritube (FCV) used during tracheostomy

    The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC (poly vinyl chloride) surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.

    Device: tritube

  • No intervention
    Group 2: Conventional endotracheal tube used during tracheostomy

    In the patient who was intubated with a conventional endotracheal tube (ETT), the tube was withdrawal to the vocal cords. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.

Interventions

  • Devicetritube

    The patient is intubated with Tritube® after the removal of the conventional endotracheal tube (ETT) and Tritube® was advanced until proximal to the carina. Before starting the PDT, measurements with ATP bioluminescence-based method (3M Clean-trace®) were made by taking sample from a sterile PVC surface (10 cm2) which is held 50 cm over the operation site. After PDT with Griggs method (Portex), the measurements were repeated by taking sample from surface.

06

What researchers measure

Primary outcomes

  1. the outcome measures (droplet account) are assessing a change

    The investigators hypothesized that droplet account will decrease while tritube using

    Time frame: 1th min before sterilization and 1th min after tracheostomy cannula insertion

Secondary outcomes

  1. complication rates

    the complications such as endotracheal tube (ET) cuff puncture, Difficult insertion of tracheostomy tube, Accidental extubation, Bleeding vs. during percutaneous tracheostomy

    Time frame: 24 hour after tracheostomy procedure

07

Study locations

1 site
  • Diskapi Training and Resource Hospital
    Ankara, Ankara 06010, Turkey (Türkiye)
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Sep 2023, 5 months.

Of 35 non-industry interventional studies with no phase under Hypoventilation, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 5 months is below that.

Counting every sponsor, half of 35 studies reached it within 15 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Apr 14, 2023
StartActual
Apr 11, 2023
Primary completionActual
Sep 14, 2023
CompletionActual
Sep 14, 2023
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05813977
Lead sponsor
Ankara Diskapi Training and Research Hospital
Responsible party
Eda Macit Aydın (Principal Investigator, specialist, intensivisit, Ankara Diskapi Training and Research Hospital) — Principal investigator
First posted
Apr 14, 2023
Start date
Apr 11, 2023
Primary completion
Sep 14, 2023
Completion
Sep 14, 2023
Last update
Jul 9, 2025

Study contacts

Eda MACİT AYDIN
principal investigator · Ankara Diskapi Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion